Journal
CELL
Volume 147, Issue 1, Pages 235-246Publisher
CELL PRESS
DOI: 10.1016/j.cell.2011.08.040
Keywords
-
Categories
Funding
- NIH/NIMH [R01 MH081754-02R]
- NIH ACE Center [1P50-HD055784-01, 5R01-MH081754-04]
- NIH [NS50220]
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Incumbent of the Hanna Hertz Professorial Chair for Multiple Sclerosis and Neuroscience
Ask authors/readers for more resources
Although many genes predisposing to autism spectrum disorders (ASD) have been identified, the biological mechanism(s) remain unclear. Mouse models based on human disease-causing mutations provide the potential for understanding gene function and novel treatment development. Here, we characterize a mouse knockout of the Cntnap2 gene, which is strongly associated with ASD and allied neurodevelopmental disorders. Cntnap2(-/-) mice show deficits in the three core ASD behavioral domains, as well as hyperactivity and epileptic seizures, as have been reported in humans with CNTNAP2 mutations. Neuropathological and physiological analyses of these mice before the onset of seizures reveal neuronal migration abnormalities, reduced number of interneurons, and abnormal neuronal network activity. In addition, treatment with the FDA-approved drug risperidone ameliorates the targeted repetitive behaviors in the mutant mice. These data demonstrate a functional role for CNTNAP2 in brain development and provide a new tool for mechanistic and therapeutic research in ASD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available